Type-1 plasminogen activator inhibitor in human renal cell carcinoma

Journal of Pathology

Volumn 179, Issue 1, 1996, Pages 95-99

  Wagner, Stephan N ^a,c   Atkinson, Michael J ^a   Thanner, Stephanie ^a   Schmitt, Manfred ^b   Wilhelm, Olaf ^b   Rotter, Michael ^b   Höfler, Heinz ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Immunohistochemistry; Invasion; Northern blot analysis; Plasminogen activator inhibitor 1; Proteolysis; Renal cell carcinoma

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; METASTASIS; NORTHERN BLOTTING; PRIORITY JOURNAL;

BLOTTING, NORTHERN; CARCINOMA, RENAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER;

EID: 0029896655     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199605)179:1<95::AID-PATH534>3.0.CO;2-Z     Document Type: Article

References (35)

1. Fromowitz FB, Bard RH Clinical implications of pathologic subtypes in renal cell carcinoma Semin Urol 1990; 8: 31-50.
2. Fiedler IJ. The biology of renal cancer metastasis Semin Urol 1992; X: 3-11
3. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991 54: 327-336.
4. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983; 35: 611-619
5. Mignatti P, Robbins E, Rifkin DB. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade Cell 1980, 47: 487-498.
6. Kirchheimer JC, Pfluger H, Heinert G, Binder BR. Increased urokinase activity to antigen ratio in human renal-cell carcinoma. Int J Cancer 1985, 35: 737-741.
7. Hata M The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator Nippon-Hinyokika-Gakkai-Zasshi 1989; 80: 1558-1565.
8. Yoneda J, Saiki I, Fujii H, Abe F, Kojima Y, Azuma I. Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (betastatin) Clin Exp Metastasis 1992; 10: 49-59.
9. Declerk PJ, De Mol M, Alessi M-C, et al Purification and characterization of plasminogen activator inhibitor 1 binding protein from human plasma J Biol Chem 1988; 263: 15454-15461.
10. Mimuro J, Maramatsu S, Kurano Y, et al Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. Biochemistry 1993; 32: 2314-2320.
11. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-β. J Cell Biol 1986, 103: 2403-2410.
12. Pöllanen J, Saksela O, Salonen E-M, et al. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells J Cell Biol 1987; 104: 1085-1096
13. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19
14. Cajot JF, Barnat J, Bergonzelli GE, et al. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA 1990 87: 6939-6943.
15. Reiter LS, Kruithof EKO, Cajot J-F, Sordat B. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells Int J Cancer 1993; 53: 111-150
16. Shirasuna K, Saka M, Hayashido Y, Yoshioka H, Sugiura T, Matsuya T Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Cancer Res 1993; 53: 147-152.
17. Eker R, Nesland JM, Andersen A, Johannessen JV. Prognostic factors in renal cell carcinoma Histol Histopathol 1986; 1: 255-270.
18. Jänicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic parameters in node-negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208
19. Chirgwin JM, Przybyla AE, McDonald RJ, Rutter WJ. Isolation of biologically active RNA from sources enriched in ribonuclease Biochemistry 1979; 18: 5294-5297.
20. Wagner SN, Ruhri C, Kunth K, et al Expression of stromelysin 3 in the stromal elements of human basal cell carcinoma. Diagn Mol Pathol 1992. 1: 200-205.
21. van den Berg EA, Sprengers ED, Jaye M, Burgess W, Maciag T, van Hinsbergh VWM. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells Thromb Haemost 1988; 60: 63-67
22. Moos M, Gallwitz D. Structure of two human β-actin-related processed genes one of which is located next to a simple repetitive sequence EMBO J 1983; 2: 757-761.
23. Cordell JL, Falini B, Erber WN, et al. Immuoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32; 219-229.
24. Mosma P, Kooistra T. Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells. J Biol Chem 1991, 266: 117845-17849.
25. Reilly DM, Andreasen PAS, Duch M, Nolan N, Lecander I, Duffy MJ Plasminogen activator inhibitor type 1 and 2 in human breast cancer. Biochem Soc Trans 1991; 20: 88S.
26. Pyke C, Kristensen P, Ralfkiær E, Enksen J, Danø K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma Cancer Rev 1991, 51: 4067-4071.
27. Sappino A-P, Belin D, Huarte J, Hirschel-Scholz S, Saurat J-H, Vassalli J-D. Differential protease expression by cutaneous squamous and basal cell carcinoma. J Clin Invest 1991; 88: 1073-1079.
28. Nakamura M, Konno H, Tanaka T, et al. Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissue Thromb Res 1992; 65: 709-719.
29. Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas Int J Cancer 1992; 50: 208-214.
30. Wagner SN, Atkinson MJ, Thanner S, et al. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol 1995; 147: 183-192.
31. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-2521.
32. Pedersen H, Grendahl-Hansen J, Francis D, et al, Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma Cancer Res 1994, 54; 120-123.
33. Pepper MS, Sappino A-P, Montesano R, Orci L, Vassalli J-D. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J Cell Physiol 1992; 153: 129-139
34. Wagner SN, Atkinson MJ, Wagner C, Höfler H, Schmitt M, Wilhelm O Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochem Cell Biol 1996; 105: 53-60
35. Heaton JH, Kathju S, Gelehrter TD Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides. Mol Endocrinol 1992; 6: 53-60.